Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance

Fig. 4

ESR1–CCDC170 forms homodimers and interacts with HER2/HER3/SRC complex. a ESR1-CCDC170 interacts with HER2, HER3, and SRC as shown by immuno-precipitation assay of T47D cells expressing wtCCDC170 or E2-E10, performed with anti-HER2, HER3, or SRC antibody, and detected by immuno-blotting with the indicated antibodies. b BiFC assay to detect the dimerization of E2-E10 fusion protein. E2-E10 ORF was either fused to the N-terminal of YFP (Yn) or the C-terminal of YFP (Yc) for plasmid constructs. HT1080 cells were then co-transfected to express indicated Yn- and Yc-tagged proteins. The histogram shows the percentage of YFP-positive cells with the reconstituted YFP signal detected by flow cytometry in the respective transfected HT1080 cells

Back to article page